Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
51 studies found for:    Open Studies | "Neurofibromatoses"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Neurofibromatoses" (51 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Neurofibromatosis Type 1 Patient Registry
Condition: Neurofibromatosis Type 1
Intervention:
2 Recruiting Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma
Condition: Neurofibromatosis Type 1
Interventions: Device: Magnetic resonance imaging;   Drug: Gadolinium contrast
3 Recruiting Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1
Condition: Neurofibromatosis Type 1
Interventions: Other: CogmedRM;   Other: Mobymax
4 Not yet recruiting Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
Condition: Neurofibromatosis Type 1 (NF1)
Intervention: Drug: Cholecalciferol
5 Recruiting Photodynamic Therapy for Benign Dermal Neurofibromas
Condition: NEUROFIBROMATOSIS 1
Intervention: Procedure: PDT Treatment
6 Recruiting Neurofibromatosis (NF) Registry Portal
Conditions: Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:
7 Recruiting Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Conditions: Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:
8 Recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
9 Recruiting Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas
Intervention: Drug: Axitinib
10 Recruiting Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Icotinib
11 Recruiting Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Other: Acceptance and Commitment Therapy (ACT)
12 Recruiting Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Condition: Neurofibromatosis 2
Interventions: Behavioral: Stress Management Group 1;   Behavioral: Stress Management Group 2
13 Recruiting Effect of Lamotrigine on Cognition in NF1
Condition: Neurofibromatosis Type 1
Interventions: Drug: Lamotrigine;   Drug: Placebo
14 Recruiting Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
Conditions: Neurofibromatosis;   MPNST
Interventions: Procedure: MRI, FDG-PET/CT scans;   Procedure: [18F]-FLT-PET/CT scans
15 Recruiting Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Intervention: Drug: Imatinib Mesylate
16 Recruiting AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Conditions: Neurofibromatosis 2;   Meningioma
Intervention: Drug: AZD2014
17 Recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
18 Recruiting Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Conditions: Cutaneous Neurofibromas;   Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Procedure: Skin Biopsy
19 Recruiting A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Conditions: Neoplasms, Nerve Tissue;   Neurofibromatosis 1;   Heredodegenerative Disorders, Nervous System;   Peripheral Nervous System Diseases
Intervention: Drug: Selumetinib (AZD6244 hyd sulfate)
20 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.